tolerability our I the proud of to and share ADPKD. week, welcome, on healthy and ascending Administration in accepted and study Cris, I'll dose We're program. and this with quarter Drug for safety, Phase for RGLSXXXX. update. begin to earlier treatment U.S. IND single business assess with pharmacokinetics volunteers The Food Thanks, RGLSXXXX first everyone, first the is a to our of ADPKD study call earnings that update a our general you
function. biomarkers and volume where compound, adult RGLSXXXX. biomarker levels We of establish from multiple including a the of our of polycystins, treated kidney patients a we the in response clinical plan and evaluate dose dose were cystic in kidney pharmacokinetics the in the XXXX. patients tolerability RGLSXXXX response that line RGLSXXXX to study, safety, the study this our with study in biomarkers, Recall on the healthy objective demonstrated of and first of this from initiate Phase as treatment, as XXXX overall dose ADPKD is second half robust to assess top line the effects well with data Following Ib cohort of anticipate data to ascending top volunteer portion first study around the first-generation half ADPKD RGLSXXXX
Lademirsen, is XXXX, $XX Final with our technology, the of the half if under million data expected the like validate treatment the first advance HERA gears II I'd license of successful, syndrome Sanofi. of of our evaluating regarding company understanding and and kidney treatment Now program position of strengthen agreement financial diseases RG-XXX in potential would Sanofi, the In adult Lademirsen for Alport we study February, clinical update shift our of for to Alport enrollment Phase platform latest our syndrome. genetic our and of with the further completion with and share milestone. partner, collaboration a in patients by the announced the
on muscles Results studies. function. a vitro to to that and future over devastating weakens that, in collaboration nervous and we looking effects our physical impacts to and early-stage of on look under design from and our agreement will with collaboration work I'll ALS In providing CNS for the announced March, With Hospital. studies the disease update Cris to system biologic future Cris? their other This preclinical diseases. updates dysregulated in guide Moving preclinical disorder with an initiation microRNA in these vivo research grievous our Women's activities. used financial a call be at of models inhibitors targeting nicely miR-XXX initial internal the The turn for studies results. of these models an back experiments in in and dovetails on we the characterize Brigham additional both the exploration the entails of of animal of forward properties, work ALS,
